Article By:
StockNews
Saturday, February 13, 2021 7:41 PM EST
While neither Astrazeneca or Novavax will have a first-mover advantage if and when their vaccines are eventually brought to market their late-stage clinical trial results of AZN and NVAX are said to show a lot of promise.
Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
The article isn’t wrong based off currently commercialized products (we have none)... and there is a chance that things could still end badly for $NVAX. But the odds are so much in our favor now that, at least for the next few weeks, investing in NVAX is like printing free money.
Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
This article states the #Novavax $NVAX is overvalued. Market cap? Revenue potential?
Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
Analyst can actually think a #Covid19 vaccine will only cost $.40 each since $NVAX has stated that they expect to produce 1 billlion doses in 2021, does he?